(Q53283207)

English

Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma: in combination with the International Prognostic Index.

scientific article published on 21 October 2004

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/15503137

Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma: in combination with the International Prognostic Index. (English)

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/15503137

author name string

Hideko Goto

1

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/15503137

Hisashi Tsurumi

2

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/15503137

Masao Takemura

3

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/15503137

Yoriko Ino-Shimomura

4

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/15503137

Senji Kasahara

5

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/15503137

Michio Sawada

6

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/15503137

Toshiki Yamada

7

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/15503137

Takeshi Hara

8

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/15503137

Kenji Fukuno

9

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/15503137

Naoe Goto

10

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/15503137

Masataka Okuno

11

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/15503137

Tsuyoshi Takami

12

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/15503137

Mitsuru Seishima

13

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/15503137

Hisataka Moriwaki

14

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/15503137

publication date

21 October 2004

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/15503137

Journal of Cancer Research and Clinical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/15503137

131

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/15503137

2

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/15503137

73-79

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/15503137

https://scigraph.springernature.com/pub.10.1007/s00432-004-0600-9

0 references

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

1 reference

https://pubmed.ncbi.nlm.nih.gov/15503137

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Elevated serum levels of soluble CD44 variant 6 are correlated with shorter survival in aggressive non-Hodgkin's lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/15503137

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/15503137

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Biweekly CHOP or THP-COP regimens in the treatment of newly diagnosed aggressive non-Hodgkin's lymphoma. A comparison of doxorubicin and pirarubicin: a randomized phase II study

1 reference

https://pubmed.ncbi.nlm.nih.gov/15503137

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The soluble interleukin-2 receptor: biology, function, and clinical application

1 reference

https://pubmed.ncbi.nlm.nih.gov/15503137

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prospects for pirarubicin

1 reference

https://pubmed.ncbi.nlm.nih.gov/15503137

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic significance of survivin expression in diffuse large B-cell lymphomas.

1 reference

https://pubmed.ncbi.nlm.nih.gov/15503137

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic value of serum interleukin-6 in diffuse large-cell lymphoma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/15503137

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Soluble interleukin-2 receptor levels in patients with undifferentiated and lymphoblastic lymphomas: correlation with survival

1 reference

https://pubmed.ncbi.nlm.nih.gov/15503137

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Soluble interleukin 2 receptors in sera of Japanese patients with adult T cell leukemia mark activity of disease.

1 reference

https://pubmed.ncbi.nlm.nih.gov/15503137

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro.

1 reference

https://pubmed.ncbi.nlm.nih.gov/15503137

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic Factors in Aggressive Non-Hodgkin's Lymphomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/15503137

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High serum levels of soluble interleukin 2 receptor in patients with B chronic lymphocytic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/15503137

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic value of serum IL-10 and soluble IL-2 receptor levels in aggressive non-Hodgkin's lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/15503137

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

(2"-R)-4'-o-tetrahydropyranyladriamycin, a new anthracycline derivative; its effectiveness in lymphoid malignancies

1 reference

https://pubmed.ncbi.nlm.nih.gov/15503137

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic significance of serum soluble interleukin-2 receptor level in non-Hodgkin's lymphoma: a single center study in Japan.

1 reference

https://pubmed.ncbi.nlm.nih.gov/15503137

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Plasma soluble interleukin-2 receptor level in patients with primary myelodysplastic syndromes: a relationship with disease subtype and clinical outcome

1 reference

https://pubmed.ncbi.nlm.nih.gov/15503137

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project

1 reference

https://pubmed.ncbi.nlm.nih.gov/15503137

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

1 reference

https://pubmed.ncbi.nlm.nih.gov/15503137

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic implications of the differentiation inhibitory factor nm23-H1 protein in the plasma of aggressive non-Hodgkin's lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/15503137

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Soluble interleukin-2 receptors (sIL-2R) in Hodgkin's disease: outcome and clinical implications

1 reference

https://pubmed.ncbi.nlm.nih.gov/15503137

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A prospective study of P-IMVP-16/CBDCA: a novel salvage chemotherapy for patients with aggressive non-Hodgkin's lymphoma who had previously received CHOP therapy as first-line chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/15503137

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Serum-soluble fas level determines clinical symptoms and outcome of patients with aggressive non-Hodgkin's lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/15503137

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A high pretreatment serum basic fibroblast growth factor concentration is an independent predictor of poor prognosis in non-Hodgkin's lymphoma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/15503137

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas: report of the jury

1 reference

https://pubmed.ncbi.nlm.nih.gov/15503137

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pirarubicin, a novel derivative of doxorubicin. THP-COP therapy for non-Hodgkin's lymphoma in the elderly

1 reference

https://pubmed.ncbi.nlm.nih.gov/15503137

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/15503137

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A high serum-soluble interleukin-2 receptor level is associated with a poor outcome of aggressive non-Hodgkin's lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/15503137

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Report of the Committee on Hodgkin's Disease Staging Classification

1 reference

https://pubmed.ncbi.nlm.nih.gov/15503137

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: updated results of the prospective study LNH87-2. Groupe d'Etude des Lymphomes de l'Adulte.

1 reference

https://pubmed.ncbi.nlm.nih.gov/15503137

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00432-004-0600-9

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/15503137

release_n5mr2p2ghbejnassuyezj3olhi

1 reference

https://api.fatcat.wiki/v0/release/n5mr2p2ghbejnassuyezj3olhi

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/15503137

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53283207&oldid=1837220859"